GlassScriptPhysician profile
Samuel Berkman
NPI 1730114752
$151,241.97
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $3,605 · 2021: $9,267 · 2022: $30K · 2023: $32K · 2024: $8,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $6,227 · Travel and Lodging: $5,809 · Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,835.00 |
| Consulting Fee | $6,227.00 |
| Travel and Lodging | $5,809.04 |
| Food and Beverage | $1,670.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $125,154.46 | 2019-2024 | Xarelto |
| Portola Pharmaceuticals, LLC | $8,734.14 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $7,546.84 | 2023 | Empaveli, Empaveli |
| Alexion Pharmaceuticals, INC. | $4,355.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $3,845.65 | 2022 | |
| Janssen Scientific Affairs, LLC | $805.24 | 2019-2024 | Xarelto |
| Vertex Pharmaceuticals Incorporated | $516.67 | 2021 | |
| Amgen INC. | $136.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.33 | 2019 | |
| Abbvie INC. | $30.17 | 2021 | |
| Novo Nordisk INC | $22.70 | 2019 | |
| Gilead Sciences, INC. | $16.77 | 2019 | |
| Pfizer INC. | $15.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Berkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.